Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disa

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

10:45am, Wednesday, 26'th Feb 2025

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

08:51am, Wednesday, 26'th Feb 2025

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics

07:35pm, Tuesday, 25'th Feb 2025

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare t

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

06:50pm, Tuesday, 25'th Feb 2025

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

04:05pm, Tuesday, 25'th Feb 2025

– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav ® and Epidiolex ® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues gre

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

04:15pm, Thursday, 20'th Feb 2025

DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management w

Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

10:20am, Thursday, 20'th Feb 2025

Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some

Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?

10:26am, Wednesday, 12'th Feb 2025

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

04:15pm, Tuesday, 11'th Feb 2025

DUBLIN , Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again

01:11pm, Wednesday, 05'th Feb 2025

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Biotech Stocks With Notable Insider Buying

12:29pm, Wednesday, 22'nd Jan 2025

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-c

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by